×
About 79,470 results

ALLMedicine™ Non-small Cell Lung Cancer Center

Research & Reviews  38,287 results

Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patie...
https://doi.org/10.21037/apm-20-2369
Annals of Palliative Medicine; Han ZJ, Luo N et. al.

May 12th, 2021 - Although tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have a favorable and durable treatment response, almost all patients will eventually acquire resistance and develop disease progression. Re-administration...

A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring r...
https://doi.org/10.21037/apm-20-2556
Annals of Palliative Medicine; Shan CG, Wang H et. al.

May 12th, 2021 - Leptomeningeal metastasis (LM) is a rare but lethal complication of advanced non-small cell lung cancer (NSCLC) that has a devastating impact on patient survival and quality of life. Osimertinib, an irreversible tyrosine kinase inhibitor, is appro...

Sublobar Resection in Stage IA Non-Small Cell Lung Cancer: Role of Preoperative CT Feat...
https://doi.org/10.2214/AJR.21.25618
AJR. American Journal of Roentgenology; Choe J, Kim MY et. al.

May 12th, 2021 - Background: Prognostic factors on preoperative CT in stage IA non-small cell lung cancer (NSCLC) may help select patients to undergo sublobar resection or lobectomy. Objective: To identify CT features predictive of pathologic lymphovascular invasi...

Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tu...
https://doi.org/10.2214/AJR.21.25814
AJR. American Journal of Roentgenology; Li C, Tian Y et. al.

May 12th, 2021 - Background: Lymphovascular invasion (LVI) is an adverse prognostic indicator in non-small cell lung cancer (NSCLC) and serves as an indication for postoperative adjuvant chemotherapy recommendation after resection. Objective: To assess the utility...

AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer.
https://doi.org/10.1073/pnas.2026104118
Proceedings of the National Academy of Sciences of the Un... Tien JC, Chugh S et. al.

May 11th, 2021 - Lung cancer is the deadliest malignancy in the United States. Non-small cell lung cancer (NSCLC) accounts for 85% of cases and is frequently driven by activating mutations in the gene encoding the KRAS GTPase (e.g., KRASG12D). Our previous work de...

see more →

Guidelines  157 results

Small Cell Lung Cancer - StatPearls
https://www.statpearls.com/articlelibrary/viewarticle/24494/
StatPearls [Internet];

Dec 31st, 2020 - Lung cancer is the second most diagnosed cancer in the United States. It is the leading cause of cancer death in both men and women, accounting for approximately a quarter of all cancer deaths. Lung cancer is histologically divided into 2 main typ...

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors
https://pubmed.ncbi.nlm.nih.gov/32746691/
Journal of Oncology Pharmacy Practice; Rosentreter J

Aug 2nd, 2020 - Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from...

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3...
https://www.jto.org/article/S1556-0864(20)30595-5/pdf
Journal of Thoracic Oncology; Yang Y

Jul 24th, 2020 - Sintilimab, an anti-programmed death 1 antibody, plus pemetrexed and platinum had shown promising efficacy for nonsquamous non-small cell lung cancer in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to compare the ef...

Adjuvant osimertinib extends DFS in EGFR-mutated NSCLC
https://www.healio.com/hematology-oncology/lung-cancer/news/online/{641f2259-d903-472a-acbb-681a7bbd3eec}/adjuvant-osimertinib-extends-dfs-in-egfr--mutated-nsclc

May 28th, 2020 - Adjuvant osimertinib significantly prolonged DFS for patients with EGFR-mutated non-small cell lung cancer, according to results of the randomized phase 3 ADAURA trial scheduled for presentation during the ASCO20 Virtual Scientific Program.

Durable Responses Elicited with Nivolumab Plus Ipilimumab in Advanced NSCLC
https://www.targetedonc.com/view/durable-responses-elicited-with-nivolumab-plus-ipilimumab-in-advanced-nsclc

May 28th, 2020 - Frontline treatment with the combination of with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced durable and long-term efficacy benefits in patients with advanced non-small cell lung cancer (NSCLC) and tumor PD-L1 expression of at least 1% or ...

see more →

Drugs  255 results see all →

Clinicaltrials.gov  39,579 results

Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patie...
https://doi.org/10.21037/apm-20-2369
Annals of Palliative Medicine; Han ZJ, Luo N et. al.

May 12th, 2021 - Although tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have a favorable and durable treatment response, almost all patients will eventually acquire resistance and develop disease progression. Re-administration...

A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring r...
https://doi.org/10.21037/apm-20-2556
Annals of Palliative Medicine; Shan CG, Wang H et. al.

May 12th, 2021 - Leptomeningeal metastasis (LM) is a rare but lethal complication of advanced non-small cell lung cancer (NSCLC) that has a devastating impact on patient survival and quality of life. Osimertinib, an irreversible tyrosine kinase inhibitor, is appro...

Sublobar Resection in Stage IA Non-Small Cell Lung Cancer: Role of Preoperative CT Feat...
https://doi.org/10.2214/AJR.21.25618
AJR. American Journal of Roentgenology; Choe J, Kim MY et. al.

May 12th, 2021 - Background: Prognostic factors on preoperative CT in stage IA non-small cell lung cancer (NSCLC) may help select patients to undergo sublobar resection or lobectomy. Objective: To identify CT features predictive of pathologic lymphovascular invasi...

Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tu...
https://doi.org/10.2214/AJR.21.25814
AJR. American Journal of Roentgenology; Li C, Tian Y et. al.

May 12th, 2021 - Background: Lymphovascular invasion (LVI) is an adverse prognostic indicator in non-small cell lung cancer (NSCLC) and serves as an indication for postoperative adjuvant chemotherapy recommendation after resection. Objective: To assess the utility...

AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer.
https://doi.org/10.1073/pnas.2026104118
Proceedings of the National Academy of Sciences of the Un... Tien JC, Chugh S et. al.

May 11th, 2021 - Lung cancer is the deadliest malignancy in the United States. Non-small cell lung cancer (NSCLC) accounts for 85% of cases and is frequently driven by activating mutations in the gene encoding the KRAS GTPase (e.g., KRASG12D). Our previous work de...

see more →

News  1,185 results

Fast Five Quiz: Squamous Cell Non-Small Cell Lung Cancer
https://reference.medscape.com/viewarticle/928233

May 4th, 2021 - Lung cancer continues to be the leading cause of cancer-related deaths worldwide. Non–small cell lung cancer (NSCLC), which accounts for 85% of all lung cancers, is divided histologically into adenocarcinoma, squamous cell carcinoma, and large cel...

Neutrophil/Lymphocyte Ratio May Be Tied to Survival in Patients Receiving Immunotherapy for NSCLC Brain Metastases
https://www.medscape.com/viewarticle/949326

Apr 15th, 2021 - NEW YORK (Reuters Health) - In patients with non-small cell lung cancer brain metastases (NSCLCBM) treated with immune-checkpoint inhibitors (ICIs) and upfront steroids, a low neutrophil-to-lymphocyte ratio (NLR) was associated with lower overall ...

Combo Immunotherapy in NSCLC: Not These Two Drugs
https://www.medscape.com/viewarticle/945603

Feb 9th, 2021 - Dual immunotherapy with pembrolizumab (Keytruda) and ipilimumab (Yervoy) did not improve survival outcomes over pembrolizumab alone in the treatment of metastatic non-small cell lung cancer (NSCLC) in the KEYNOTE-598 trial. However, the combinatio...

Neoadjuvant Atezolizumab Safe in Resectable Lung Cancer
https://www.medscape.com/viewarticle/945607

Feb 9th, 2021 - Neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients with stage IB-IIIB lung cancer and produced a 21% major pathologic response rate, according to the primary analysis of the Lung Cancer Mutation Consortium (LCMC) ...

US Cancer Death Rates Drop for Second Year in a Row
https://www.medscape.com/viewarticle/944030

Jan 12th, 2021 - For the second year in a row, mortality from cancer has fallen in the United States, driven largely by reductions in the incidence of, and death from, non-small cell lung cancer (NSCLC) in men and women, according to a new report from the American...

see more →

Patient Education  7 results see all →